Real-World Effectiveness of Ravulizumab Among Adults with Atypical Hemolytic Uremic Syndrome (aHUS) Who Switched to Ravulizumab within 3 Months of Eculizumab Treatment: A Physician Panel-Based Chart Review Study (aHUS IMPACT)
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Shruti Chaturvedi, Yan Wang, Moh-Lim Ong, Arpita Nag, Rui Song, Lynn Huynh, Jordan A. Burdeau, Mei Sheng Duh, Ramy Magdy Hanna
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4405035235